These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1916 related items for PubMed ID: 26240506

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, Okada AA, Iida T, Sekiryu T.
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [Abstract] [Full Text] [Related]

  • 3. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M, Todorova MG, Masyk M, Wolf K, Rickmann A, Helaiwa K, Blanke BR, Szurman P.
    BMC Ophthalmol; 2017 May 23; 17(1):79. PubMed ID: 28535756
    [Abstract] [Full Text] [Related]

  • 4. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH, Sun HJ, Lee SJ.
    Int Ophthalmol; 2017 Oct 23; 37(5):1205-1214. PubMed ID: 27826933
    [Abstract] [Full Text] [Related]

  • 5. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
    Kanadani TCM, Veloso CE, Nehemy MB.
    Ophthalmologica; 2018 Oct 23; 240(4):200-207. PubMed ID: 29768266
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term switching between ranibizumab and aflibercept in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH, Kim JW, Kim CG, Lee DW.
    Graefes Arch Clin Exp Ophthalmol; 2020 Aug 23; 258(8):1677-1685. PubMed ID: 32361804
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Kim JH, Kim CG, Lee DW, Yoo SJ, Lew YJ, Cho HJ, Kim JY, Lee SH, Kim JW.
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan 23; 258(1):107-116. PubMed ID: 31741044
    [Abstract] [Full Text] [Related]

  • 9. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K.
    BMC Ophthalmol; 2016 Jul 27; 16():127. PubMed ID: 27465105
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N, Dirani A, Butel N, Fardeau C, Bodaghi B, Ingram A, Lehoang P.
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan 27; 255(1):61-67. PubMed ID: 27397583
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
    Morimoto M, Matsumoto H, Mimura K, Akiyama H.
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct 27; 255(10):1891-1897. PubMed ID: 28669041
    [Abstract] [Full Text] [Related]

  • 14. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
    Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T.
    Retina; 2014 Nov 27; 34(11):2192-201. PubMed ID: 25077530
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Hosokawa MM, Ouchi C, Shiode Y, Kimura S, Matoba R, Morita T, Morizane Y.
    Graefes Arch Clin Exp Ophthalmol; 2024 Oct 27; 262(10):3099-3107. PubMed ID: 38625447
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 96.